Objective
To study the mRNA expressions of various CD97 isoforms in colorectal carcinoma tissues and their clinical significances.
Methods
A total of 50 colon cancer patients in the First Affiliated Hospital of Wenzhou Medical University from December 2013 to May 2014 and human colon cancer cell lines SW480 and SW620 were enrolled. The real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) was used to detect the mRNA expressions of CD97 human epidermal growth factor (EGF) (1, 2, 5), CD97EGF (1, 2, 3, 5) and CD97EGF (1, 2, 3, 4, 5) in colon cancer tissues, adjacent tissues, normal colon tissues, SW480 cells and SW620 cells. The relationship between the mRNA expression of CD97EGF (1, 2, 5) and the clinicopathological factors was analyzed.
Results
Compared with those low expressions in adjacent tissues and normal tissues, the mRNA expressions of CD97 isoforms CD97EGF (1, 2, 5), CD97EGF (1, 2, 3, 5) and CD97EGF (1, 2, 3, 4, 5) in cancer tissues were highest, and the differences were statistically significant (0.71±0.20 vs. 0.40±0.09 vs. 0.35±0.07, F = 107.642, P < 0.01; 0.45±0.11 vs. 0.26±0.05 vs. 0.27±0.06, F = 94.231, P < 0.01; 0.41±0.10 vs. 0.21±0.05 vs. 0.19±0.03, F = 165.672, P < 0.01). In addition, the mRNA expression of CD97EGF (1, 2, 5) in colon cancer patients was associated with tumor infiltration depth (T1-T2 and T3-T4), clinical stages (Ⅰ-Ⅱ and Ⅲ-Ⅳ), and the differences were statistically significant (t = -2.582, P = 0.013; t = -5.062, P < 0.01). The mRNA expression of CD97EGF (1, 2, 5) in SW620 cells was higher than that in SW480 cells.
Conclusions
CD97 isoforms are highly expressed in colon cancer tissues, and CD97EGF (1, 2, 5) may play an important role in the development and invasion of colon cancer. The CD97 isoforms may be new markers in the treatment of colon cancer.
Key words:
Colonic neoplasms; Isoform, CD97; Reverse transcriptase polymerase chain reaction; Pathology, clinical
Abstract Previous reports had shown that the survival rate of total mastectomy (TM) was better than that of breast-conserving surgery (BCS). This study established survival prediction models for T1 LABC mastectomy and BCS, and obtained the risk factors for OS of different surgical procedures, so as to provide a basis for clinicians to individualized treatment.Cases with pathologically confirmed T1 breast cancer (BC) between 2010 and 2015 in the Surveillance, Epidemiology, and End Results (SEER) database were identified. COX regression analysis was used to analyze the relationship between LABC TM, BCS and each factor, and the hazard ratio (HR) and 95% confidence interval (95%CI) were calculated to determine the possible influencing factors. The significant factors from multivariate COX regression were included in the model and then the nomogram was drawn. The receiver operating characteristic (ROC) curve of the model was drawn, and the area under the curve (AUC) and its 95% CI were calculated. Hosmer-Lemeshow goodness-of-fit test was performed. The results were validated in the validation group. The 5-year overall survival (OS) and breast cancer specific survival (BCSS) of BCS were higher than those of TM. Age, race, histological grade, N stage, molecular typing, chemotherapy and radiotherapy (RT) were correlated with 5-year OS of BCS, and age, race, pathological type, histological grade, human epidermal growth factor receptor-2 (Human epidermal growth factor receptor 2, HER2) status, N stage, molecular typing, chemotherapy and RT were related to 5-year OS of TM. The predictive nomogram was established using the above predictors, and the AUC of the modeling group was 0.743 (BCS 5-year OS) and 0.718 (TM 5-year OS), respectively. All models were well validated in the validation group. This study found that the survival rate of BCS group was better than that of TM group, and it indicated the effect of tumor size on BCS survival, while lymph node status was not a risk factor for BCS, BCS could be considered for LABC patients with small masses and more lymph node metastases. However, the risk of death after BCS in patients with N3, triple-negative and upper-inner quadrant primary tumors was higher than that in other groups, and BCS should be cautious in these patients.
Abstract Background: Some patients with breast cancer are diagnosed with locally advanced breast cancer (LABC). At present, there are no obvious reports on LABC radiotherapy, chemotherapy, and breast-conserving benefit population. Method: The cases of LABC confirmed by pathology from 2010 to 2015 were searched through the Surveillance Epidemiology and End Results (SEER) database. Breast cancer-specific survival (BCSS) and overall survival (OS) were estimated by plotting Kaplan-Meier curves. The log rank test (Mantel-Cox) was used to analyze the difference between the groups, and the benefit population of LABC was determined after for age, TNM stage, grade, treatment methods. Results: A total of 34474 LABC patients were included, 22477 (65.2%) were Luminal A, 1418 (4.1%) were Luminal B, 4911 (14.3%) were triple-negative breast cancer, 2461 (7.1%) were HER2-enriched, and 3207 (9.3%) were three positive breast cancer. Kaplan-Meier curves of 5-year OS and BCSS were plotted for LABC patients with different molecular types of breast conserving surgery and mastectomy. Overall the LABC with breast conserving and total mastectomy was 77.8%, 84.6% ,68.4% and 77.2%. Luminal A LABC with breast conserving and total mastectomy was 79.9%,87.5%, 72.3% and 81.5%.Luminal B LABC with breast-conserving and total mastectomy were 79.3% , 83.1%, 70.8% and 77.1%. TNBC LABC with breast-conserving and total mastectomy were 61.0% ,68.4%, 47.5% and 56.2%. HER2-enriched LABC with breast-conserving and total mastectomy were 77.7%, 80.5%, 67.2% and 75.2%. TPBC LABC with breast-conserving and total mastectomy were 84.9%, 91.8%, 75.5% and 82.1%, respectively. Except for the Luminal B LABC BCSS surgery method, there was no significant difference (P=0.058), all the others were statistically significant (P<0.05). Conclusions: This study found that in the selective population, OS and BCSS of patients with LABC undergoing breast conserving surgery were significantly better than those of mastectomy.This study also found that LABC could be considered for highly differentiated, NO stage TPBC without chemotherapy.
C-X-C motif chemokine ligand 12 (CXCL12) may play an important role in the development of Intracranial Aneurysm (IA).The goal of this study was to explore the association between CXCL12 rs1746048 genotypes and circulating lipid concentrations along with the risk of IA.A total of 256 IA patients and 361 healthy volunteers were included in the case-control study. The genotypes of CXCL12 rs1746048 were detected by Melting Temperature shift (Tmshift) Polymerase Chain Reaction (PCR).Significant higher levels were seen in Total Cholesterol (TC) (padjusted < 0.001), Highdensity Lipoprotein Cholesterol (HDL-C) (padjusted < 0.001), Low-density Lipoprotein Cholesterol (LDL-C) (padjusted < 0.001), Apolipoprotein A-I (ApoA-I) (padjusted = 0.040), and Apolipoprotein B (ApoB) (padjusted < 0.001) in IAs compared with controls. CXCL12 rs1746048 T allele frequency showed significant association with the risk of IA in the female group aged 65 or above (p = 0.019, Odds Ratio (OR) = 2.15, 95% confidence interval (95%CI) = 1.13 - 4.11, power = 64.8%). Moreover, CXCL12 rs1746048 was likely to be a risk variant of IA under the recessive model in females older than 65 years. (p = 0.030, OR = 3.77, 95%CI = 1.08 - 13.12, power = 81.8%). Additionally, we also found that the levels of LDL-C were significantly different among three genotypes (CC vs. CT vs. TT = 2.75±0.73 vs. 3.03±0.89 vs. 2.82±0.72, p = 0.035) in IA patients.Our results suggest that CXCL12 rs1746048 is significantly associated with IA risk in Han Chinese females aged 65 years and older. Additionally, the genotypes of CXCL12 rs1746048 may affect the LDL-C concentrations in IA patients.
Although the research reports on locally advanced breast cancer (LABC) are increasing year by year, there are few reports on T1 LABC axillary lymph node metastasis (ALNM). By establishing a prediction model for T1 LABC ALNM, this study provides a reference value for the probability of ALNM of related patients, which helps clinicians to develop a more effective and individualized treatment plan for LABC.
This meta-analysis aimed to evaluate the diagnostic accuracy of touch imprint cytology (TIC) for sentinel lymph node (SLN) metastases of patients with clinical node-negative early breast cancer. The PubMed, Web of Science, Embase, and the Cochrane Library databases were meticulously searched to retrieve literature published from January 2005 to September 2022 by two independent reviewers. The meta-analysis was performed using STATA16.0, Meta-Disc 1.4, and RevMan 5.4.9. According to the inclusion criteria, 4,073 patients from 13 studies were included in this meta-analysis. The pooled sensitivity and specificity of TIC for detecting SLN metastases were 0.77 (95% CI 0.66-0.85) and 0.99 (95% CI 0.97-1.00), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 76.15 (95% CI 29.16-198.84) and 0.23 (95% CI 0.15-0.36), respectively. The pooled diagnostic odds ratio was 326.82 (95% CI 132.76-804.56) and the area under the sROC curve was 0.97 (95% CI 0.95-0.98), respectively. This meta-analysis revealed that TIC with high sensitivity and specificity is a feasibility and accuracy diagnosis technique for intraoperative detection of SLN metastases in breast cancer.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)